NEWS
-
Hongmin Chen joins WARF Therapeutics
Chen to head biology for program aiming to produce preclinical candidates CONTACT: Jeanan Yasiri Moe Director of Strategic Communications [email protected] | (608) 960-9892 MADISON, Wis. – WARF Therapeutics, the multimillion-dollar…
-
WARF Therapeutics fall 2021 call for proposals
Program proposal deadline October 8 CONTACT: Jeanan Yasiri Moe Director of Strategic Communications [email protected] | (608) 960-9892 MADISON, Wis. – WARF Therapeutics collaborates with researchers to advance their work closer…
-
WARF Therapeutics spring 2021 call for proposals
Program proposal deadline April 5 CONTACT: Jeanan Yasiri Moe Director of Strategic Communications [email protected] | (608) 960-9892 MADISON, Wis. – WARF Therapeutics collaborates with researchers to advance their work closer…
-
WARF Therapeutics 2020 call for fall proposals
CONTACT: Jacqui Fuller, Strategic Communications and Marketing Manager [email protected] | 608.960.9881 Fall WARF Therapeutics (WT) Program Proposal Deadline: October 15 MADISON, Wis. – WARF Therapeutics encourages researchers working on a…
EVENTS
-
Wed 13April 13 @ 10:30 am - 11:30 amMechanisms of Malignant Transformation of the Immune System and Precision Therapies for Lymphomas – Ari Melnick
Mechanisms of Malignant Transformation of the Immune System and Precision Therapies for Lymphomas – Ari Melnick
Dr. Ari Melnick received his M.D. from the University of Buenos Aires School of Medicine, Argentina in 1990. He continued his medical and postdoctoral training at Mount Sinai School of…
-
Thu 21April 21 @ 2:00 pm - 5:00 pmWARF Therapeutics Symposium
WARF Therapeutics Symposium
Join WARF Therapeutics, the UW-Madison Department of Chemistry and the UW-Madison Synthesis and Catalysis Center for a symposium that will highlight innovative chemistry and its integration into pharmaceutical discovery and…
-
Fri 6May 6 @ 3:30 pm - 4:30 pmNovel Therapeutic Approaches to Target Movement Disorders: Discovery to Clinic – Craig Lindsley
Novel Therapeutic Approaches to Target Movement Disorders: Discovery to Clinic – Craig Lindsley
This lecture will discuss the basic pharmacology of Parkinson’s disease and dystonia, target identification and validation with novel GPCR ligands. Specifically, Craig Lindsley will discuss the development of mGlu4 PAMs…
For business questions, contact John Nagel or Rafael Diaz. If you are a PI interested in submitting your work to the program or talking through next steps, contact Jon Young. You do not need to have a patent; we are interested in talking with you about a new target early in your process.